Timing. Relevance. Relationships.
Fundz is the only platform that reads more than a dozen real‑time signals all day, every day, so you know about new funding, new executives and new contracts within minutes of them happening, not days or weeks later like the databases you’re used to. It then combines the signals on each company, scores every company against what you offer, and weaves in your own network, so you discover new accounts first and work existing ones better.
Each morning you get the ones worth your time right now: who to reach, why now, and who you already know there. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Ensysce Biosciences
Acquired Company
Cy Biopharma
La JollaManufacturingBiotechnologyHealthcareHardwareFinancial ServicesFinanceFintechLendingBankingBiotechnologyHealth CarePharmaceuticalBiopharmaDescription
Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Former Cy shareholders will hold approximately 75% of the combined entity, effectively integrating Cy's pipeline into Ensysce.
Fundz sees it the moment Ensysce Biosciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Cy Biopharma?
Cy Biopharma was acquired by Ensysce Biosciences, based in La Jolla. The deal was reported on August 7, 2026. Ensysce Biosciences, Inc. Ensysce Biosciences is publicly traded (ENSC) and operates in Manufacturing.
When did Ensysce Biosciences acquire Cy Biopharma?
Ensysce Biosciences's acquisition of Cy Biopharma was reported on August 7, 2026. Ensysce Biosciences has acquired Cy Biopharma for USD 77 million to enhance its pain therapeutics portfolio. With this acquisition, Ensysce shifts from an opioid focus to include neuroplastogenic therapies for complex regional pain syndrome. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Cy Biopharma do?
Cy Biopharma is a biopharmaceutical firm developing therapies for pain conditions. They focus on neuroplastogenic approaches to treat chronic pain syndromes. Their lead asset is a neuroplastogenic receptor agonist for complex regional pain syndrome. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.